Table 2.

TEAEs in patients who continued on monotherapy (≥ 5% in Either Treatment Group)

TEAEs, n (%)	Patients, n (%)
	Trastuzumab-dkst (N = 179)		Trastuzumab (N = 164)
	All grades	Grade ≥ 3	All grades	Grade ≥ 3
Any TEAE	124 (69.3)	23 (12.8)	119 (72.6)	31 (18.9)
Headache	19 (10.6)	0	23 (14.0)	4 (2.4)
Hypertension	12 (6.7)	2 (1.1)	9 (5.5)	1 (0.6)
Increased ALT	11 (6.1)	2 (1.1)	7 (4.3)	3 (1.8)
Vomiting	10 (5.6)	0	7 (4.3)	0
Decreased ejection fraction	10 (5.6)	0	6 (3.7)	1 (0.6)
Upper respiratory tract infection	10 (5.6)	0	4 (2.4)	0
Increased AST	9 (5.0)	1 (0.6)	7 (4.3)	3 (1.8)
Fatigue	9 (5.0)	0	7 (4.3)	0
Arthralgia	9 (5.0)	0	3 (1.8)	0
Cough	9 (5.0)	0	3 (1.8)	0
Anemia	6 (3.4)	0	17 (10.4)	2 (1.2)
Peripheral neuropathy	5 (2.8)	0	9 (5.5)	0

ALT alanine aminotransferase, AST aspartate aminotransferase